An international controlled clinical study published in The New England Journal of Medicine demonstrates that liquid biopsy can help identify…
ESMO2025
Reported at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, results from four multicenter early phase…
Results from the multicenter, open-label, randomized phase 3 DESTINY Breast11 trial show that neoadjuvant antibody-drug conjugate trastuzumab deruxtecan improved pathological…
Results from the LITESPARK-015 open-label, multicohort phase 2 trial show that hypoxia-inducible factor-2 alpha inhibitor belzutifan achieves durable antitumor activity…
The results of the international phase 3 MATTERHORN clinical trial show that adding the antibody durvalumab, an immune checkpoint inhibitor,…
